Inclusion Criteria:

          -  Stage III/IV, locally advanced, biopsy proven squamous cell cancer of the head and
             neck that undergo chemoradiation as their primary treatment with curative intent.

          -  Oropharynx (HPV positive and HPV negative), hypopharynx, larynx primaries, nasopharynx
             as well as those with documented SCC of the cervical lymph nodes, with unknown
             primaries.

          -  >10 pack years of tobacco use

          -  Age ≥ 18 years

          -  ECOG performance status ≤ 2

          -  At least one site of measurable disease

          -  Adequate bone marrow function as shown by: ANC > 1.5 x 109/L, Platelets >100 x 109/L,
             Hb >9 g/dL

          -  Total calcium (corrected for serum albumin) within normal limits

          -  Magnesium ≥ the lower limit of normal

          -  Potassium within normal limits for the institution.

          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal
             range

          -  Serum bilirubin within normal range (or ≤ 1.5 x ULN if liver metastases are present;
             or total bilirubin ≤ 3.0 x ULN with direct bilirubin within normal range in patients
             with well documented Gilbert Syndrome)

          -  Serum creatinine ≤ 1.5 x ULN or 24-hour clearance ≥ 50 mL/min

          -  Serum amylase ≤ ULN

          -  Serum lipase ≤ ULN

          -  Fasting plasma glucose ≤ 120 mg/dL (6.7 mmol/L)

          -  Signed informed consent

          -  INR ≤ 2

        Exclusion Criteria:

          -  Distant metastatic disease

          -  Less than or equal to 10 pack years of tobacco history

          -  Received prior chemotherapy

          -  Received prior radiation to the head and neck or adjacent anatomical site

          -  Received prior treatment with a P13K inhibitor.

          -  Known hypersensitivity to BKM120 or to its excipients

          -  Acute or chronic liver, renal disease or pancreatitis

          -  Mood disorders ≥ CTCAE grade 3

          -  Diarrhea ≥ CTCAE grade 2

          -  Active cardiac disease

          -  History of cardiac dysfunction including any of the following:

          -  Patient has poorly

          -  Impairment of gastrointestinal (GI) function

          -  Currently receiving treatment with medication with a known risk to prolong the QT
             interval or inducing Torsades de Pointes and the treatment cannot either be
             discontinued or switched to a different medication prior to starting study drug.

          -  Chronic treatment with steroids or another immunosuppressive agent.

          -  Herbal medications and certain fruits within 7 days prior to starting study drug.

          -  Currently treated with drugs known to be moderate and strong inhibitors or inducers of
             isoenzyme CYP3A, and the treatment cannot be discontinued or switched to a different
             medication prior to starting study drug. Please refer to Appendix B for a list of
             prohibited inhibitors and inducers of CYP3A (Please note that co-treatment with weak
             inhibitors of CYP3A is allowed).

          -  Undergone major surgery ≤ 2 weeks prior to starting study drug or who have not
             recovered from side effects of such therapy.

          -  Currently taking therapeutic doses of warfarin sodium or any other coumadin-derivative
             anticoagulant.

          -  Women who are pregnant or breast feeding or adults of reproductive potential not
             employing an effective method of birth control.

          -  Known diagnosis of human immunodeficiency virus (HIV) infection

          -  History of another malignancy within 3 years, except cured basal cell carcinoma of the
             skin or excised carcinoma in situ of the cervix